Table: Aska Pharmaceutical Holdings -Q1 group results

ASKA Pharmaceutical Holdings

04/08/2026 07:32

    Aug 4 (Reuters)- 
             Aska Pharmaceutical Holdings Co., Ltd. 
             CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                 3 months ended      3 months ended       Year to 
                Jun 30, 2026        Jun 30, 2025     Mar 31, 2027 
                   LATEST             YEAR-AGO          LATEST    
                   RESULTS             RESULTS         FORECAST   
  Sales             17.38               17.64            73.00    
                 (-1.5 pct)          (+7.9 pct)       (+2.6 pct)  
  Operating        711 mln               1.46             6.20    
                 (-51.4 pct)         (-16.7 pct)      (+6.3 pct)  
  Recurring        817 mln               1.59             6.10    
                 (-48.7 pct)         (-12.1 pct)      (+7.7 pct)  
  Net              533 mln               1.26             4.80    
                 (-57.5 pct)         (-1.4 pct)       (-11.5 pct) 
  EPS             18.78 yen           44.27 yen       169.11 yen  
  Ann Div                             60.00 yen        65.00 yen  
  -Q2 div                             27.00 yen        32.00 yen  
  -Q4 div                             33.00 yen        33.00 yen  
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd.. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T